Congenital adrenal hyperplasia: Do the benefits of prenatal treatment defeat the risks?

Obstetrical and Gynecological Survey

Volumn 65, Issue 3, 2010, Pages 196-205

  Vos, Amber A ^a   Bruinse, Hein W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; FLUDROCORTISONE; HYDROCORTISONE; HYDROXYPROGESTERONE; MINERALOCORTICOID; ORAL CONTRACEPTIVE AGENT; PREDNISONE; SODIUM CHLORIDE; STEROID 21 MONOOXYGENASE;

ACNE; BEHAVIOR CHANGE; BLOOD SAMPLING; CHILD; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; CORTICOSTEROID THERAPY; CORTICOTROPIN RELEASE; FEMALE FERTILITY; FEMALE PSEUDOHERMAPHRODITISM; GENE MUTATION; HIRSUTISM; HORMONE BLOOD LEVEL; HUMAN; MALE FERTILITY; MORNING DOSAGE; NEUROPSYCHOLOGY; NEWBORN SCREENING; PATHOPHYSIOLOGY; PRENATAL CARE; RECOMMENDED DRUG DOSE; REVIEW; STEROID 21 MONOOXYGENASE DEFICIENCY; TREATMENT OUTCOME; UROGENITAL SINUS; VIRILIZATION;

ADRENAL HYPERPLASIA, CONGENITAL; ADRENOCORTICOTROPIC HORMONE; BEHAVIOR; DEXAMETHASONE; FEMALE; FERTILITY; FETAL THERAPIES; GLUCOCORTICOIDS; HUMANS; MALE; PREGNANCY; PRENATAL CARE; SEX FACTORS; STEROID 21-HYDROXYLASE; VIRILISM;

EID: 77949388479     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3181d61046     Document Type: Review

References (76)

1. Forest MG. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update 2004;10:469-485.
2. New MI, Carlson A, Obeid J, et al. Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 2001;86:5651-5657.
3. New MI, White PC. Genetic disorders of steroid hormone synthesis and metabolism. Baillieres Clin Endocrinol Metab 1995;9:525-554.
4. Villee DB. The development of steroidogenesis. Am J Med 1972;53:533-544.
5. McKenna TJ, Jennings AS, Liddle GW, et al. Pregnenolone, 17-OH-pregnenolone, and testosterone in plasma of patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1976;42:918-925.
6. Kuhnle U, Rosler A, Pareira JA, et al. The effects of long-term normalization of sodium balance on linear growth in disorders with aldosterone deficiency. Acta Endocrinol 1983;102:577-582.
7. Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998;101(4 pt 1):583-590.
8. Casteràs A, De Silva P, Rumsby G, Conway GS. Pregnancy rate but reduced fertility rate. Clin Endocrinol (Oxf). 2009 Jun;70(6):833-837.
9. Krone N, Dhir V, Ivison HE, et al. Congenital adrenal hyper-plasia and P450 oxidoreductase deficiency. Clin Endocrinol 2007;66:162-172.
10. Speiser PW, Dupont B, Rubinstein P, et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985;37:650-667.
11. Claahsen-van der Grinten HL, Hoefsloot LH. From gene to disease: adrenogenital syndrome and the CYP21A2 gene [in Dutch]. Ned Tijdschr Geneeskd 2007;151:1174-1177.
12. Speiser PW, New MI. Genotype and hormonal phenotype in nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 1987;64:86-91.
13. Levine LS, Zachmann M, New MI, et al. Genetic mapping of the 21-hydroxylase-deficiency gene within the HLA linkage group. N Engl J Med 1978;299:911-915.
14. Kawaguchi H, O'HUigin C, Klein J. Evolutionary origin of mutations in the primate cytochrome P450c21 gene. Am J Hum Genet 1992;50:766-780.
15. White PC, Grossberger D, Onufer BJ, et al. Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proc Natl Acad Sci USA 1985;82:1089-1093.
16. Carroll MC, Campbell RD, Porter RR. Mapping of steroid 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man. Proc Natl Acad Sci USA 1985;82:521-525.
17. Speiser PW, Dupont J, Zhu D, et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992;90:584-595.
18. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005;365:2125-2136.
19. Jaaskelainen J, Levo A, Voutilainen R, et al. Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population. J Clin Endocrinol Metab 1997;82:3293-3297.
20. Wilson RC, Mercado AB, Cheng KC, et al. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. J Clin Endocrinol Metab 1995;80:2322-2329.
21. Krone N, Braun A, Roscher AA, et al. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyp-ing in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 2000;85:1059-1065.
22. New MI. An update of congenital adrenal hyperplasia. Ann N Y Acad Sci 2004;1038:14-43.
23. Lajic S, Nordenstrom A, Ritzen EM, et al. Prenatal treatment of congenital adrenal hyperplasia. Eur J Endocrinol 2004; 151(suppl 3):U63-U69.
24. Kurtoglu S, Atabek ME, Keskin M, et al. Acanthosis nigricans in association with congenital adrenal hyperplasia: resolution after treatment: case report. Turk J Pediatr 2005;47:183-187.
25. New MI, Lorenzen F, Lerner AJ, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 1983;57:320-326.
26. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003;349:776-788.
27. Joint LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002;87: 4048-4053.
28. Trakakis E, Loghis C, Kassanos D. Congenital adrenal hyper-plasia because of 21-hydroxylase deficiency. A genetic disorder of interest to obstetricians and gynecologists. Obstet Gynecol Surv 2009;64:177-189.
29. Gatelais F, Berthelot J, Beringue F, et al. Effect of single and multiple courses of prenatal corticosteroids on 17-hydroxyprogesterone levels: implication for neonatal screening of congenital adrenal hyperplasia. Pediatr Res 2004;56: 701-705.
30. Klingensmith GJ, Garcia SC, Jones HW, et al. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 1977;90: 996-1004.
31. Kulshreshtha B, Marumudi E, Khurana ML, et al. Fertility among women with classical congenital adrenal hyperplasia: report of seven cases where treatment was started after 9 years of age. Gynecol Endocrinol 2008;24:267-272.
32. Jones HW Jr, Verkauf BS. Congenital adrenal hyperplasia: age at menarche and related events at puberty. Am J Obstet Gynecol 1971;109:292-298.
33. Lo JC, Grumbach MM. Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia. Endocrinol Metab Clin North Am 2001;30:207-229.
34. Mulaikal RM, Migeon CJ, Rock JA. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1987;316:178-182.
35. Premawardhana LD, Hughes IA, Read GF, et al. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol 1997;46:327-332.
36. Hagenfeldt K, Janson PO, Holmdahl G, et al. Fertility and pregnancy outcome in women with congenital adrenal hyper-plasia due to 21-hydroxylase deficiency. Hum Reprod 2008; 23:1607-1613.
37. Hoepffner W, Schulze E, Bennek J, et al. Pregnancies in patients with congenital adrenal hyperplasia with complete or almost complete impairment of 21-hydroxylase activity. Fertil Steril 2004;81:1314-1321.
38. Malouf MA, Migeon CJ, Carson KA, et al. Cognitive outcome in adult women affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2006;65:142-150.
39. Ghali I, David M, David L. Linear growth and pubertal development in treated congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol 1977;6:425-436.
40. Urban MD, Lee PA, Migeon CJ. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 1978;299:1392-1396.
41. Reisch N, Flade L, Scherr M, et al. High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2009;94:1665-1670.
42. Stikkelbroeck NM, Otten BJ, Pasic A, et al. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86: 5721-5728.
43. Claahsen-van der Grinten HL, Otten BJ, Sweep FC, et al. Repeated successful induction of fertility after replacing hy-drocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors. Fertil Steril 2007;88:705.e5-705.e8.
44. Berenbaum SA, Resnick SM. Early androgen effects on aggression in children and adults with congenital adrenal hyper-plasia. Psychoneuroendocrinology 1997;22:505-515.
45. Pasterski V, Hindmarsh P, Geffner M, et al. Increased aggression and activity level in 3-to 11-year-old girls with congenital adrenal hyperplasia (CAH). Horm Behav 2007;52:368-374.
46. Mathews GA, Fane BA, Conway GS, et al. Personality and congenital adrenal hyperplasia: possible effects of prenatal androgen exposure. Horm Behav 2009;55:285-291.
47. Green R, Roberts CW, Williams K, et al. Specific cross-gender behaviour in boyhood and later homosexual orientation. Br J Psychiatry 1987;151:84-88.
48. Hines M, Kaufman FR. Androgen and the development of human sex-typical behavior: rough-and-tumble play and sex of preferred playmates in children with congenital adrenal hyperplasia (CAH). Child Dev 1994;65:1042-1053.
49. Pang S, Levine LS, Cederqvist LL, et al. Amniotic fluid concentrations of delta 5 and delta 4 steroids in fetuses with congenital adrenal hyperplasia due to 21 hydroxylase deficiency and in anencephalic fetuses. J Clin Endocrinol Metab 1980;51:223-229.
50. Speiser PW, Laforgia N, Kato K, et al. First trimester prenatal treatment and molecular genetic diagnosis of congenital adrenal hyperplasia (21-hydroxylase deficiency). J Clin Endocri-nol Metab 1990;70:838-848.
51. Forest MG, Betuel H, David M. Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study. Endocr Res 1989;15:277-301.
52. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-487.
53. Rijnders RJ, Christiaens GC, de Haas M, et al. Fetal DNA in maternal blood [in Dutch]. Ned Tijdschr Geneeskd 2004;148: 170-174.
54. Mercado AB, Wilson RC, Cheng KC, et al. Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1995;80:2014-2020.
55. Carlson AD, Obeid JS, Kanellopoulou N, et al. Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. J Steroid Biochem Mol Biol 1999;69:19-29.
56. Lajic S, Wedell A, Bui TH, et al. Long-term somatic follow-up of prenatally treated children with congenital adrenal hyper-plasia. J Clin Endocrinol Metab 1998;83:3872-3880.
57. Lajic S, Nordenstrom A, Hirvikoski T. Long-term outcome of prenatal treatment of congenital adrenal hyperplasia. Endocr Dev 2008;13:82-98.
58. Trautman PD, Meyer-Bahlburg HF, Postelnek J, et al. Mothers' reactions to prenatal diagnostic procedures and dexa-methasone treatment of congenital adrenal hyperplasia. J Psychosom Obstet Gynaecol 1996;17:175-181.
59. Hirvikoski T, Nordenstrom A, Lindholm T, et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab 2007;92:542-548.
60. Meyer-Bahlburg HF, Dolezal C, Baker SW, et al. Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. J Clin Endocrinol Metab 2004;89:610-614.
61. Heine VM, Rowitch DH. Hedgehog signaling has a protective effect in glucocorticoid-induced mouse neonatal brain injury through an 11betaHSD2-dependent mechanism. J Clin Invest 2009;119:267-277.
62. Welberg LA, Seckl JR, Holmes MC. Prenatal glucocorticoid programmingofbraincorticosteroidreceptorsandcorticotrophin-releasing hormone: possible implications for behaviour. Neuroscience 2001;104:71-79.
63. Slotkin TA, Kreider ML, Tate CA, et al. Critical prenatal and postnatal periods for persistent effects of dexamethasone on serotonergic and dopaminergic systems. Neuropsychophar-macology 2006;31:904-911.
64. Seckl JR, Miller WL. How safe is long-term prenatal glucocor-ticoid treatment? JAMA 1997;277:1077-1079.
65. Hauser J, Knapman A, Zurcher NR, et al. Effects of prenatal dexamethasone treatment on physical growth, pituitary-adrenal hormones, and performance of motor, motivational, and cognitive tasks in juvenile and adolescent common marmoset monkeys. Endocrinology 2008;149:6343-6355.
66. Murphy BP, Inder TE, Huppi PS, et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics 2001;107:217-221.
67. Baud O. Postnatal steroid treatment and brain development. Arch Dis Child Fetal Neonatal Ed. 2004;89:F96-F100.
68. Parikh NA, Lasky RE, Kennedy KA, et al. Postnatal dexameth-asone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics 2007;119:265-272.
69. Barker DJ, Hales CN, Fall CH, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36:62-67.
70. Benediktsson R, Lindsay RS, Noble J, et al. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 1993;341:339-341.
71. Celsi G, Kistner A, Aizman R, et al. Prenatal dexamethasone causes oligonephronia, sodium retention, and higher blood pressure in the offspring. Pediatr Res 1998;44:317-322.
72. Merke DP. Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocri-nol Metab 2008;93:653-660.
73. Stikkelbroeck NM, Oyen WJ, van der Wilt GJ, et al. Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyper-plasia. J Clin Endocrinol Metab 2003;88:1036-1042.
74. Volkl TM, Simm D, Beier C, et al. Obesity among children and adolescents with classic congenital adrenal hyperpla-sia due to 21-hydroxylase deficiency. Pediatrics 2006;117: e98-e105.
75. Cornean RE, Hindmarsh PC, Brook CG. Obesity in 21-hydroxylase deficient patients. Arch Dis Child 1998;78:261-263.
76. Sartorato P, Zulian E, Benedini S, et al. Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocri-nol Metab 2007;92:1015-1018.